Market Overview:
The global deferoxamine mesylate market is expected to grow at a CAGR of 5.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing prevalence of anemia, rising awareness about the benefits of deferoxamine mesylate, and growing demand for deferoxamine mesylate in emerging markets. However, factors such as the high cost of treatment and lack of reimbursement policies are restraining the growth of this market. The global deferoxamine mesylate market is segmented on the basis of type, application, and region. On the basis of type, it is divided into ≥98% purity and other types. On the basis on application, it is classified into anemia treatment, acute iron poisoning treatment,, and other applications. Geographically speaking, it covers North America (U.S., Canada), Latin America (Mexico), Europe (Germany France Italy Spain U K Rest Of Europe), Asia Pacific (Japan China India Australia South Korea Rest Of Asia Pacific) Middle East & Africa(GCC Countries Turkey Nigeria South Africa Rest Of MEA).
Product Definition:
A chelating agent used to remove excess iron from the body. It is given by injection.
≥98% Purity:
Deferoxamine mesylate is a drug that is used to treat moderate to severe obstructive sleep apnea. It works by opening airways, thereby enabling oxygen-rich blood to flow through the body and wakefulness promoting effect. The product has gained huge popularity among patients suffering from this disease as it offers better rest than other conventional drugs available in the market.
Other:
Other is used in the formulation of deferredoxamine mesylate, a drug used to treat parasitic diseases. It is also known as deoxycholic acid and sold under various brand names such as D Defer, Dechra-Lan, and Lanreotide. Other ingredients include hydroxypropyl methyl cellulose and stearic acid.
Deferoxamine mesylate has been approved by the Food.
Application Insights:
The acute iron poisoning segment held the largest share of 24.5% in 2017. The segment is anticipated to witness a lucrative CAGR over the forecast period owing to an increase in cases of accidental and deliberate acute iron poisoning including industrial accidents, suicide attempts using pesticides, and murders by giving poisoned drinks or food with hidden ingredients.
Deferoxamine mesylate is used for treating various diseases such as anemia due to chronic renal failure, heavy metal toxicity (including lead), hypoxic-ischemic encephalopathy (HIE), osteoporosis caused by rheumatoid arthritis or other conditions such as cancer chemotherapy induced nausea & vomiting along with improving quality of life. These factors are expected to drive deferoxamine mesylate demand over the forecast period thereby propelling global market growth during the study period.
Regional Analysis:
Europe was the largest market for deferoxamine mesylate, accounting for a share of more than 35.0% in 2017 owing to the high prevalence of iron deficiency anemia in this region. In addition, increasing number of patients suffering from chronic kidney disease and liver diseases are expected to drive the demand for DFOXM as well as other drugs containing deferoxamine in Europe during the forecast period.
Asia Pacific is anticipated to be one of the fastest-growing markets with a CAGR close to 6.5% over the forecast period on account of rising incidence rates related to anemia and iron deficiency anemia especially among women coupled with increasing awareness about available treatment options among end-users including healthcare professionals.
In addition, growing medical tourism industry due to low cost associated with these treatments will further propel growth over coming years.
Growth Factors:
- Increasing prevalence of iron-deficiency anemia: The increasing prevalence of iron-deficiency anemia is one of the key growth drivers for the deferoxamine mesylate market. According to a study by World Health Organization (WHO), it is estimated that around 2 billion people are affected by iron-deficiency anemia, out of which, nearly half are women and children. This number is expected to increase in the coming years due to the rising population and changing dietary habits. This will create a high demand for deferoxamine mesylate products, thereby driving the market growth.
- Growing awareness about Iron Deficiency Anemia: There has been a growing awareness about Iron Deficiency Anemia in recent years among both patients and healthcare professionals alike. This has led to an increased demand for treatments such as deferoxamine mesylate, which can help address this condition effectively. As more people become aware about this condition and its treatment options, the market for deferoxamine mesylate is expected to grow further in future.
Scope Of The Report
Report Attributes
Report Details
Report Title
Deferoxamine Mesylate Market Research Report
By Type
≥98% Purity, Other
By Application
Anemia, Acute Iron Poisoning, Other
By Companies
Teva api, Chengdu Easton Biopharmaceuticals, Pharmapex Group, New-In CO.
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
157
Number of Tables & Figures
110
Customization Available
Yes, the report can be customized as per your need.
Global Deferoxamine Mesylate Market Report Segments:
The global Deferoxamine Mesylate market is segmented on the basis of:
Types
≥98% Purity, Other
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Anemia, Acute Iron Poisoning, Other
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Teva api
- Chengdu Easton Biopharmaceuticals
- Pharmapex Group
- New-In CO.
Highlights of The Deferoxamine Mesylate Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- ≥98% Purity
- Other
- By Application:
- Anemia
- Acute Iron Poisoning
- Other
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Deferoxamine Mesylate Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Deferoxamine mesylate is a medication used to treat iron overload in patients with anemia. It works by removing excess iron from the body.
Some of the major companies in the deferoxamine mesylate market are Teva api, Chengdu Easton Biopharmaceuticals, Pharmapex Group, New-In CO..
The deferoxamine mesylate market is expected to register a CAGR of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Deferoxamine Mesylate Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Deferoxamine Mesylate Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Deferoxamine Mesylate Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Deferoxamine Mesylate Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Deferoxamine Mesylate Market Size & Forecast, 2020-2028
4.5.1 Deferoxamine Mesylate Market Size and Y-o-Y Growth
4.5.2 Deferoxamine Mesylate Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 ≥98% Purity
5.2.2 Other
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Anemia
6.2.2 Acute Iron Poisoning
6.2.3 Other
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Deferoxamine Mesylate Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Deferoxamine Mesylate Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 ≥98% Purity
9.6.2 Other
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Anemia
9.10.2 Acute Iron Poisoning
9.10.3 Other
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 ≥98% Purity
10.6.2 Other
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Anemia
10.10.2 Acute Iron Poisoning
10.10.3 Other
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 ≥98% Purity
11.6.2 Other
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Anemia
11.10.2 Acute Iron Poisoning
11.10.3 Other
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 ≥98% Purity
12.6.2 Other
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Anemia
12.10.2 Acute Iron Poisoning
12.10.3 Other
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 ≥98% Purity
13.6.2 Other
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Anemia
13.10.2 Acute Iron Poisoning
13.10.3 Other
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Deferoxamine Mesylate Market: Competitive Dashboard
14.2 Global Deferoxamine Mesylate Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Teva api
14.3.2 Chengdu Easton Biopharmaceuticals
14.3.3 Pharmapex Group
14.3.4 New-In CO.
